BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, January 24, 2025
See today's BioWorld
Home
» Elan-Wyeth Alzheimer's Trial Suspended Due to Skin Lesion
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Elan-Wyeth Alzheimer's Trial Suspended Due to Skin Lesion
April 21, 2008
By
Catherine Hollingsworth
No Comments
A Phase II trial of the ACC-011 compound for Alzheimer's disease being developed by Elan Corp. plc and Wyeth Pharmaceuticals has been suspended due to a skin lesion observed in a single patient. (BioWorld Today)
BioWorld
